A

AbbVie

Global biopharmaceutical company developing medicines

Field Coverage Representative - Inside Sales Pharma

Full-TimeUpdated on 10/23/2026
$27 - $48.80/hr+ Short-term incentive program
Junior
Bachelor's
Austin, TX, USA
Hybrid50% field-based and 50% hybrid from the Austin office; onsite Tuesday–Thursday and remote Monday/Friday. Travel up to 50–70%.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree or equivalent experience is required.
  • At least one year of relevant sales experience is required.
  • A proven track record of exceeding sales targets in an environment incentivized by established goals and metrics is required.
  • Candidates must be able to work independently and be highly organized, with strong communication skills.
  • Candidates must demonstrate clinical techniques and understand medical terminology.
  • Candidates must demonstrate professional phone etiquette.
  • Candidates must be able to use Microsoft Office, including Outlook, Word, Excel, and PowerPoint.
  • Candidates must be clinically oriented, pronounce medical terms accurately, and engage key targets in person and by phone within the territory to increase prescription knowledge and adherence where clinically appropriate.
  • Candidates must learn and apply mandatory best practices, including daily activity, goals, and metrics; expedient use of databases and other core tools; strict quality control standards and performance monitoring; input on call quality, job aids, and targeted improvement opportunities; established escalation pathways; and partnership with field sales, operations, and marketing to improve effectiveness.
Responsibilities
  • Provide in-person and virtual vacancy coverage for field sales vacancies.
  • Use sales techniques with an assigned list of healthcare professionals to provide product education, cost and access information, samples, literature, resources, program recruitment, and follow-up conversations.
  • Facilitate account management, including pre-call planning, field resource coordination, closing, customer education and resource support, and reporting.
  • Build and maintain productive business relationships in person and by phone.
  • Demonstrate clinical, technical, and presentation skills.
  • Identify, prioritize, and drive opportunities that create access, programs, and processes to drive product demand.
  • Engage targeted healthcare professionals in informational and promotional communications in accordance with program policies and procedures.
  • Complete required data entry, document interaction details and follow-up actions, and maintain data integrity in accordance with policies and procedures.
  • Profile and manage a targeted list of healthcare professionals and provide value-added benefits to grow product volume.
  • Manage daily sales call activity to optimize time and achieve sales and market-share objectives.
  • Listen and respond to customer questions and needs, seeking acceptance of or agreement with the call-plan objective.
  • Maintain product expertise, including competitive product knowledge.
  • Maintain thorough product knowledge and communicate product information clearly, concisely, and accurately using proper medical terminology within compliance guidelines.
  • Complete product and compliance training, including self-study, testing, field work, and classroom or electronic training, and meet training expectations for servicing customers within program parameters.
  • Work independently and in a team environment.
  • Meet and exceed established call-volume metrics and sales-attainment goals, leading to executable activity.
  • Establish, grow, and retain relationships with healthcare professionals at all levels, including office staff, medical assistants, nurses, and doctors.
  • Process customer requests for product samples and resources accurately and promptly.
  • Answer questions about securing product samples and literature, including mandatory delivery signatures.
  • Direct customers to additional product information sources, such as websites, programs, or other appropriate company resources.
  • Project a professional company image in interactions with customers and internal partners.
  • Resolve customer issues, concerns, and questions promptly while maintaining a positive, customer-focused approach.
  • Manage call activity and messaging according to approved best practices and compliance regulations.
  • Maintain training and resource materials and keep them current with program updates.
  • Communicate effectively and promptly with the Inside Sales Manager.
  • Safeguard patient privacy and confidentiality by following HIPAA Privacy and Security Rules.
  • Mentor and coach less experienced Inside Sales Representatives.
  • Assist the team manager with escalations and complex issue management when the manager is unavailable.
  • Travel up to 50–70% for in-field vacancy coverage, national conferences, and training, with flexibility to adapt to occasional changes in travel plans and schedules.
Desired Qualifications
  • A background in direct selling with a proven sales track record is ideal.
  • Experience in the healthcare industry involving interaction with physicians and office staff is preferred.
  • Knowledge of medical devices, pharmaceuticals, or a related field is desired.
  • Knowledge of Salesforce is preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.